FDA Moves to Ease Restrictions on Compounded Peptides

2026-10-16 companies

Washington, Friday, 16 October 2026.
The FDA proposed a policy to temporarily allow pharmacies to compound certain restricted peptides, opening access to a multi-billion-dollar market as commercial firms structure distribution strategies.

DataMeds Endorses Federal Policy Shift

On October 16, 2026, DataMeds AI, Inc. (NASDAQ:MEDS) issued a statement supporting the U.S. Food and Drug Administration’s new policy proposal, titled “Interim Access Policy for Compounding Using Certain Peptides” [1]. This regulatory update follows a recommendation made by the Pharmacy Compounding Advisory Committee less than three months prior, around July 2026, to loosen restrictions on six specific peptides [1]. The proposal was submitted to the White House Office of Management and Budget for review on October 8, 2026, marking a significant step in the Trump administration’s health agenda [4]. DataMeds indicated that its Corexa Health divisions across pharmacy, distribution, and health technology are positioned to serve the emerging market demand created by these rules [1]. Gerald Commissiong, Interim Co-CEO of DataMeds, stated the company was pleased to see the FDA act quickly on the advisory committee’s recommendations [1]. The company plans to formalize contracts with drug substance providers in the coming weeks, pending the policy’s enactment [1].

The regulatory landscape has been evolving rapidly, with the Department of Health and Human Services submitting the interim access policy for regulatory review earlier in the month [8]. Health Secretary Robert F. Kennedy Jr. had previously directed the FDA to reconsider a list of specific chemicals promoted by wellness influencers, aiming to shift production away from gray market sources in China toward U.S. compounding pharmacies [4]. This move aligns with the “Make America Healthy Again” movement’s agenda to broaden access to these compounds [8]. DataMeds intends to market peptide offerings to patients currently using the gray market and is leveraging technology licensed from REBOOT to support patients on FDA-approved GLP-1 receptor agonist drugs [1]. The company’s Health Lives Here mobile application is part of this strategic integration [1].

Regulatory Timeline and Safety Considerations

Despite the optimistic corporate response, regulatory finalization remains pending. As of October 13, 2026, legal analysts noted that no official policy had been finalized, and businesses were cautioned that current discussions do not constitute permission to dispense previously restricted substances [2]. The FDA has explicitly identified safety concerns regarding peptides, specifically citing BPC-157 due to limitations in safety information and challenges in characterizing the active pharmaceutical ingredient [2]. FDA career staff have expressed opposition to the proposed policy, citing concerns regarding patient safety and the integrity of the drug approval process [2]. In March 2026, the FDA issued a warning letter explicitly relying on website evidence to classify products as human drugs, despite existing “research use only” disclaimers [2].

Industry observers note that compounded drugs remain unapproved by the FDA and do not undergo standard premarket review for safety, effectiveness, or quality [2]. Enforcement discretion does not alter the underlying statutes or grant approval status [2]. Potential conditions for pharmacies under the contemplated policy include state licensure, valid prescriptions, enhanced patient disclosures, mandatory serious adverse event reporting, and data collection on peptide usage [2]. On social media, medical professionals have highlighted the tension between access and regulation, with one physician noting on October 13, 2026, that wanting compounding access implies a desire for regulation [7]. The FDA is evaluating a potential narrowing or withdrawal of its enforcement discretion policy regarding compounded peptides, prompting pharmacies to prepare contingency plans [2].

Market Projections and Infrastructure Readiness

The financial stakes are substantial, with the U.S. compounding pharmacy market projected to expand from $18 billion in 2025 to over $34 billion annually by 2035 [1]. This represents a growth rate of 88.889 percent over the decade [1]. Wall Street analysts estimate the potential market value for these specific peptides at $2 billion to $3 billion, prompting telehealth providers like Hims & Hers and Noom to announce plans to offer these products pending federal deregulation [4]. Corexa Distribution, a subsidiary of DataMeds, operates a 3,716 square meter warehouse in Lakeland, Florida, licensed in all 50 U.S. states to serve as a wholesale purchaser and third-party logistics provider [1]. This facility is intended to serve as a 3PL provider for peptide manufacturers and utilize its network of over 6,500 independent pharmacies to facilitate peptide access [1].

Confirmation of the federal review process has circulated through multiple channels, including social media posts from industry participants confirming the FDA submitted a proposed interim policy to the White House [6]. Reuters also reported via social media that the FDA took a step to change peptide compounding policy, linking to further details [3]. Corexa Pharmacy, a 503A compounding pharmacy subsidiary of DataMeds, intends to begin to fill prescriptions for peptides eligible for compounding under FDA’s interim policy once it goes into effect [1]. The hub receiving the prescriptions from physicians is positioned to see significant growth as physicians increasingly become the conduit for consumers to procure peptides eligible for compounding [1]. However, companies must wait for the actual written policy to determine eligibility and scope before investing [2].

Strategic Outlook and Compliance Risks

Corexa Health is navigating regulatory and operational factors related to the FDA’s policy, specifically concerning finalization, peptide eligibility, and potential enforcement modifications [1]. Corexa Pharmacy aims to compound and dispense peptides compliant with Section 503A of the Federal Food, Drug, and Cosmetic Act, USP standards, and state pharmacy laws [1]. The company maintains relationships and strategic partnerships with NFL Alumni Health, Tollo Health, and is pursuing transactions with DataVault AI Inc. (NASDAQ: DVLT), Scilex Holding Company, EOS Holdings, and HealthBridge Advisors [1]. Operations are subject to various risks, including compliance with Nasdaq listing standards, liquidity requirements, and competition from telehealth platforms [1].

Healthcare organizations are advised to treat the current regulatory environment as a strategic planning window to prepare for potential reclassification of peptides [5]. As of March 13, 2026, no formal FDA reclassification guidance had been published, and the governing regulatory framework remained unchanged [5]. If reclassification to Category 1 occurs, healthcare leaders anticipate market shifts requiring preparation in clinical pathway standardization, supply chain verification, and margin modeling [5]. Category 1 status does not equate to FDA approval of a finished drug product; it only permits compounding under interim policy while the substance remains under evaluation [5]. Ultimately, the commercial value for pharmacies and prescribers remains dependent on the specific, written terms of any regulatory update [2].

Sources

Pharmaceuticals Peptides